| 1 |
31143073 | Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. | 2019 May 14 |
1 |
| 2 |
31355968 | Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse. | 2019 Dec |
1 |
| 3 |
29288514 | High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease. | 2018 Aug |
1 |
| 4 |
30141214 | Findings from a large Asian chronic hepatitis C real-life study. | 2018 Dec |
1 |
| 5 |
30145562 | Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. | 2018 Aug 24 |
2 |
| 6 |
28579812 | Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis. | 2017 |
2 |
| 7 |
28688129 | Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. | 2017 Dec |
1 |
| 8 |
27196675 | Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies. | 2016 Oct |
1 |
| 9 |
27456384 | High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. | 2016 Oct |
1 |
| 10 |
26096332 | Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. | 2015 Oct |
1 |
| 11 |
26218843 | Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. | 2015 |
2 |
| 12 |
24342953 | Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. | 2014 |
1 |
| 13 |
24379617 | Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. | 2013 Dec 21 |
1 |